Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2024 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
February 02, 2024 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
January 05, 2024 08:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively - Patient enrollment in Phase 1b/2a SPOTLIGHT study of briquilimab in CIndU...
January 02, 2024 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. Announces Reverse Stock Split

REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
December 18, 2023 16:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
November 09, 2023 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
August 11, 2023 16:05 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

First Patient Dosed in Phase 1 trial of Briquilimab in Lower-Risk Myelodysplastic SyndromeStrengthened the Board of Directors and Management Team with Multiple Appointments REDWOOD CITY, Calif., Aug....
May 12, 2023 16:05 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

Announced Planned Development Expansion of Briquilimab in Chronic Spontaneous UrticariaPresented Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in...
November 10, 2022 16:05 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Positive Clinical Data Presented at IEWP Annual Meeting from Investigator Sponsored Study of JSP191 Conditioning Showed 100% Donor Chimerism in First Two Fanconi Anemia PatientsFast Track Designation...
May 12, 2022 16:05 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Successful meeting with the FDA; the Company intends to initiate registrational studies in MDS and AML in Q1-2023Clinical data from the Phase 1 study of JSP191 as a conditioning regimen in patients...